BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 02:59:59 2024-04-25 am EDT			5-day change	1st Jan Change
11.5 ^GBX	0.00%		0.00%	+9.52%

Apr. 17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN
Apr. 17	BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	MT

Bivictrix selects clinical candidate for leukaemia trial

June 06, 2023 at 08:54 am EDT

Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Nominates a clinical candidate for its BVX001 programme after data from a clinical study into the Bi-Cygni antibody drug conjugate showed significant tumour regressions with no observed adverse effects in acute myeloid leukaemia.

BVX001 targets the cancer-specific twin antigen fingerprint of CD7+CD33+, which is present only on the leukaemic cancer cells enabling them to be selectively targeted, while leaving healthy white blood cells alone.

Chief Executive Officer Tiffany Thorn says: "We will continue to progress BVX001 through further preclinical studies towards obtaining regulatory approval to initiate human trials, while seeking suitable third-party partnerships to support manufacturing and clinical development activities as well as commercialisation of the asset."

Current stock price: 13.95 pence, up 7.3% on Tuesday

12-month change: down 39%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about BiVictriX Therapeutics Plc

Bivictrix granted FDA orphan drug status for rare cancer treatment	Apr. 17	AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	Apr. 17	MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	Dec. 05	CI
Bivictrix selects final sequences for lead tumour programme	Nov. 30	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	Nov. 30	CI
BiVictriX patent boost; 4Global deal extended	Nov. 15	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	Nov. 15	MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	Nov. 15	RE
Bivictrix says BVX001 increases survival rates by more than double	23-10-12	AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	23-10-12	MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	23-10-12	RE
Bivictrix hires new CFO as Alex Hughes steps down after seven months	23-10-03	AN
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	23-10-03	MT
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	23-10-03	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	23-10-03	CI
AEW UK REIT appoints new chair; Oberon raises money	23-09-19	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	23-09-19	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-19	CI
AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress	23-08-23	AN
Bivictrix Therapeutics granted US patent for cancer drug BVX001	23-08-23	AN
BiVictriX Therapeutics Secures US Patent for Lead Asset	23-08-23	MT
Bivictrix Therapeutics raises GBP2.1 million through fundraise	23-07-19	AN
Bivictrix to raise more than GBP2 million via placing	23-07-19	AN
Bivictrix Therapeutics hails positive data in final leukaemia study	23-07-17	AN
Bivictrix Therapeutics hails positive leukaemia test results	23-06-19	AN

Chart BiVictriX Therapeutics Plc

Duration

Period

More charts

Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâs novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.115 GBP

Average target price

0.66 GBP

Spread / Average Target

+473.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIVICTRIX THERAPEUTICS PLC	+9.52%	11.8M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.07%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research